Navigation Links
Pharmatech 2.0: Introducing Pharmatech Oncology
Date:1/5/2009

DENVER, Jan. 5 /PRNewswire/ -- Pharmatech, Inc. announces the launch of a new campaign, Pharmatech 2.0, to highlight the company's focus in oncology, along with other key company developments that will take place in early January 2009. The next generation of Pharmatech will feature a name change from Pharmatech, Inc. to Pharmatech Oncology, Inc., as well as a new web site and emerging roles and responsibilities of the executive leadership team.

With the start of 2009, all business will be managed under the name Pharmatech Oncology, Inc. The Pharmatech Board of Directors implemented the name change from the parent company of Pharmatech, Inc. to the subsidiary name of Pharmatech Oncology. Anders Malm, current President, states, "There was a need in the marketplace for better recognition of what type of business Pharmatech was involved in. Changing from Pharmatech to Pharmatech Oncology relays a core understanding that Pharmatech works within the cancer arena."

The leadership team at Pharmatech Oncology will also be undergoing a transformation in roles and titles. Current Chief Executive Officer, Matthew B. Wiener, PharmD, will now take over the daily business operations under the title Chairman and Chief Operating Officer. Anders Malm, current President, will now replace Dr. Wiener as CEO. Pharmatech Oncology also welcomes Rob Bohacs as the new Corporate Development Manager.

Pharmatech Oncology will also introduce a new web site, http://www.pharmatechoncology.com. The launch of the new web site will showcase a more functional format, along with easy navigation capabilities. The current web site http://www.pharmatech.com will point to the new address at http://www.pharmatechoncology.com.

About Pharmatech Oncology:

Pharmatech Oncology, headquartered in Denver, Colorado, is a Research Management Organization (RMO) dedicated to the highest quality of clinical research. Pharmatech Oncology provides services of a Site Management Organization (SMO) and a Contract Research Organization (CRO) with a focus in oncology clinical trials. Through an organized research network, the Company focuses on the development and utilization of therapeutic products among sponsors, investigators, and patients. For more information about Pharmatech Oncology, please visit www.pharmatechoncology.com.


'/>"/>
SOURCE Pharmatech, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. WuXi PharmaTech Will Focus U.S. Operations on Laboratory Testing Services
2. WuXi PharmaTech Appoints Ying Han to Its Board of Directors
3. WuXi PharmaTech Announces Third Quarter 2008 Results
4. WuXi PharmaTech Signs New Collaboration Agreement With Pfizer
5. WuXi PharmaTech Schedules Third Quarter 2008 Earnings Release on Wednesday, November 12, 2008
6. WuXi PharmaTech Announces Preliminary Third Quarter 2008 Results and Updates 2008 Guidance
7. WuXi PharmaTech Appoints Jeff Leng to Its Board of Directors
8. Matthew B. Wiener, CEO of Pharmatech, Inc., Is Awarded the Cancer Leadership Award From the Colorado Cancer Coalition
9. WuXi PharmaTech (NYSE:WX) Maintains Original Strategy to Provide Toxicology Services in China
10. WuXi PharmaTech Promotes Dr. Rujian Ma to VP of Synthetic Chemistry
11. Warburg Pincus Acquires 5.4% of WuXi PharmaTechs Outstanding Ordinary Shares from United Overseas Bank
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... ... October 10, 2017 , ... For the ... won a US2020 STEM Mentoring Award. Representatives of the FirstHand program travelled to ... Experience from US2020. , US2020’s mission is to change the trajectory of STEM ...
(Date:10/10/2017)... , Oct. 10, 2017 International research firm Parks Associates ... will speak at the TMA 2017 Annual Meeting , October 11 ... in the residential home security market and how smart safety and security ... Parks Associates: ... "The residential security ...
(Date:10/10/2017)... (PRWEB) , ... October 10, 2017 , ... ... innovation and business process optimization firm for the life sciences and healthcare industries, ... conference in San Francisco. , The presentation, “Automating GxP Validation for Agile ...
(Date:10/9/2017)...  BioTech Holdings announced today identification and patenting ... stem cell therapy prevents limb loss in animal ... that treatment with ProCell resulted in more than ... to standard bone marrow stem cell administration.  Interestingly, ... of therapeutic effect.  ...
Breaking Biology Technology:
(Date:4/17/2017)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... its 2016 Annual Report on Form 10-K on Thursday April 13, ... ... the Investor Relations section of the Company,s website at http://www.nxt-id.com ... http://www.sec.gov . 2016 Year Highlights: ...
(Date:4/11/2017)... , April 11, 2017 Crossmatch®, ... secure authentication solutions, today announced that it has ... Advanced Research Projects Activity (IARPA) to develop next-generation ... program. "Innovation has been a driving ... Thor program will allow us to innovate and ...
(Date:4/11/2017)... NXT-ID, Inc. (NASDAQ:   NXTD ) ... appointment of independent Directors Mr. Robin D. Richards ... Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive ... their guidance and benefiting from their considerable expertise as we ...
Breaking Biology News(10 mins):